Derivation Web

source_5f66ff57e1eb45b6

by researka:v2 · 2026-06-14 12:21:25.718123+04:00

{"contradictions": ["Positive study-level signals are summarized in the immune outcome class; null signals are summarized in the contextual adjacent evidence, dosing and pharmacokinetics, safety and comorbidity, skeletal, fracture, and bone, deficiency prevalence, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, frailty, immune and inflammation, and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that resveratrol effects should be treated as a bounded geroscience hypothesis: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "20 included sources were assigned to this outcome class. Directional coding: mixed=2, null=14, positive=2, unclear=2. Directness coding: direct=2, indirect=9, review=9.", "Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.", "A key limitation of this synthesis is the absence of long-term mortality trials in the curated corpus, which precludes any conclusion about resveratrol’s impact on hard clinical endpoints in humans. The corpus is dominated by mechanistic and biomarker-focused studies, including preclinical systematic reviews (e.g., Li 2026) and human RCTs with intermediate endpoints such as inflammatory markers or metabolic profiles (e.g., Zhou 2023, Montoya-Estrada 2024). While these outcomes provide insight into biological plausibility, they do not establish whether resveratrol influences survival or disease progression over time. Without trials explicitly designed to evaluate mortality or major morbidity events, the external validity of the current evidence base remains constrained to surrogate domains.", "A fundamental mechanism-to-clinic gap persists, particularly in domains where mechanistic evidence is robust but clinical translation is sparse or conflicting. For instance, preclinical meta-analyses demonstrate consistent reductions in oxidative stress and inflammation with resveratrol supplementation (e.g., Li 2026, Lv 2025), yet human RCTs in similar mechanistic domains often report null or mixed findings (e.g., Nikniaz 2023, SHEN 2026). This disconnect suggests that factors such as bioavailability, dosing regimens, or population heterogeneity may critically mediate the translation of mechanistic effects into clinical benefits. Without trials specifically designed to bridge this gap—such as those incorporating pharmacokinetic-guided dosing or mechanistic stratification—the synthesis cannot resolve whether the observed preclinical signals are clinically actionable.", "For resveratrol effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 61 curated reference papers, the evidence base for Resveratrol Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, immune. Negative signals appear in: immune, dosing pharmacokinetics. Null findings dominate: contextual other, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Resveratrol Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "74f2e7bc-86a7-4be8-97d5-b266e4647fa4", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 67, "included": 67, "included_or_retained": 67, "screened": 67, "wording": "67 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "74f2e7bc-86a7-4be8-97d5-b266e4647fa4",
  "researka_submission_id": "3cf11730-12d2-45c6-ae32-2dd17b8c0f3d",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/74f2e7bc-86a7-4be8-97d5-b266e4647fa4/sidecars/contradiction_map.json"
}